Guggenheim Capital’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.73M Sell
11,333
-333
-3% -$51K 0.01% 750
2025
Q4
$1.61M Sell
11,666
-566
-5% -$74.1K 0.01% 739
2025
Q3
$1.57M Buy
12,232
+278
+2% +$33.9K 0.01% 767
2025
Q2
$1.45M Sell
11,954
-1,761
-13% -$198K 0.01% 762
2025
Q1
$1.53M Buy
13,715
+1,147
+9% +$122K 0.01% 717
2024
Q4
$1.22M Sell
12,568
-1,706
-12% -$182K 0.01% 825
2024
Q3
$1.64M Sell
14,274
-5,745
-29% -$652K 0.01% 884
2024
Q2
$2.13M Buy
20,019
+3,516
+21% +$353K 0.02% 793
2024
Q1
$1.6M Buy
16,503
+269
+2% +$27.6K 0.01% 976
2023
Q4
$1.64M Buy
16,234
+1,960
+14% +$189K 0.01% 929
2023
Q3
$1.45M Sell
14,274
-340
-2% -$34.5K 0.01% 934
2023
Q2
$1.47M Sell
14,614
-1,337
-8% -$134K 0.01% 985
2023
Q1
$1.47M Buy
15,951
+4,330
+37% +$378K 0.01% 989
2022
Q4
$1.05M Buy
11,621
+5,905
+103% +$497K 0.01% 1133
2022
Q3
$435K Buy
5,716
+289
+5% +$24K ﹤0.01% 1533
2022
Q2
$458K Sell
5,427
-504
-8% -$44.2K ﹤0.01% 1613
2022
Q1
$520K Sell
5,931
-3,527
-37% -$305K ﹤0.01% 1676
2021
Q4
$828K Buy
9,458
+1,648
+21% +$137K ﹤0.01% 1456
2021
Q3
$639K Sell
7,810
-1,179
-13% -$106K ﹤0.01% 1645
2021
Q2
$820K Sell
8,989
-2,920
-25% -$260K ﹤0.01% 1596
2021
Q1
$1.02M Sell
11,909
-4,577
-28% -$411K 0.01% 1395
2020
Q4
$1.56M Sell
16,486
-6,477
-28% -$566K 0.01% 1096
2020
Q3
$2M Sell
22,963
-5,345
-19% -$463K 0.01% 898
2020
Q2
$2.47M Sell
28,308
-1,190
-4% -$103K 0.02% 787
2020
Q1
$2.43M Sell
29,498
-3,557
-11% -$317K 0.02% 704
2019
Q4
$3.13M Sell
33,055
-5,588
-14% -$501K 0.02% 848
2019
Q3
$3.36M Buy
38,643
+4,264
+12% +$383K 0.03% 791
2019
Q2
$3.14M Sell
34,379
-14,966
-30% -$1.27M 0.03% 844
2019
Q1
$4.25M Buy
49,345
+13,062
+36% +$1.05M 0.03% 706
2018
Q4
$2.79M Sell
36,283
-14,675
-29% -$1.14M 0.02% 872
2018
Q3
$3.93M Buy
50,958
+6,288
+14% +$465K 0.03% 857
2018
Q2
$3.02M Sell
44,670
-3,844
-8% -$265K 0.02% 1011
2018
Q1
$3.52M Buy
48,514
+1,270
+3% +$96.7K 0.01% 1237
2017
Q4
$3.56M Sell
47,244
-8,516
-15% -$643K 0.01% 1240
2017
Q3
$4.29M Buy
55,760
+2,020
+4% +$153K 0.01% 1161
2017
Q2
$4.02M Buy
53,740
+4,829
+10% +$342K 0.01% 1141
2017
Q1
$3.25M Buy
48,911
+5,436
+13% +$362K 0.01% 1288
2016
Q4
$2.84M Sell
43,475
-40,948
-49% -$2.66M 0.01% 1412
2016
Q3
$5.97M Buy
84,423
+19,508
+30% +$1.42M 0.02% 917
2016
Q2
$4.8M Sell
64,915
-19,641
-23% -$1.36M 0.02% 1025
2016
Q1
$5.49M Sell
84,556
-7,881
-9% -$536K 0.02% 948
2015
Q4
$7.13M Sell
92,437
-63,248
-41% -$5.02M 0.02% 879
2015
Q3
$12.8M Sell
155,685
-22,795
-13% -$2.03M 0.04% 661
2015
Q2
$15.7M Buy
178,480
+3,652
+2% +$335K 0.04% 674
2015
Q1
$15.4M Sell
174,828
-4,164
-2% -$369K 0.04% 701
2014
Q4
$14.9M Sell
178,992
-22,009
-11% -$1.82M 0.04% 706
2014
Q3
$17M Sell
201,001
-11,191
-5% -$905K 0.04% 704
2014
Q2
$17.2M Buy
212,192
+3,506
+2% +$276K 0.04% 712
2014
Q1
$15.9M Buy
208,686
+29,961
+17% +$2.18M 0.05% 718
2013
Q4
$12.9M Buy
178,725
+37,648
+27% +$2.62M 0.04% 748
2013
Q3
$9.7M Buy
141,077
+16,172
+13% +$1.07M 0.03% 854
2013
Q2
$7.91M Buy
+124,905
New +$8.13M 0.03% 868

Other funds holding NVS

Guggenheim Capital's NVS Position: Q1 2026 in Review

Guggenheim Capital reduced its Novartis (NVS) stake by 2.9% in Q1 2026, selling an estimated $51K and leaving 11,333 shares worth $1.73M. The position accounts for 0.01% of the portfolio, ranked #750.

Guggenheim Capital first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.2M in Q2 2014. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Guggenheim Capital held 11,333 shares of Novartis worth $1.73M as of Q1 2026.
  • Guggenheim Capital sold 333 Novartis shares in Q1 2026, an estimated $51K.
  • Novartis made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #750 holding.
  • Guggenheim Capital first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's Novartis position peaked at $17.2M in Q2 2014.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.